EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Y-mAbs Therapeutics's enterprise value is $601.33 Mil.
Y-mAbs Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-24.94 Mil. Therefore, Y-mAbs Therapeutics's EV-to-EBITDA for today is -24.11.
The historical rank and industry rank for Y-mAbs Therapeutics's EV-to-EBITDA or its related term are showing as below:
YMAB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.81 Med: -5.93 Max: -0.27
Current: -24.11
During the past 8 years, the highest EV-to-EBITDA of Y-mAbs Therapeutics was -0.27. The lowest was -31.81. And the median was -5.93.
YMAB's EV-to-EBITDA is ranked worse than 100% of 468
companies
in the Biotechnology industry
Industry Median: 9.155
vs YMAB: -24.11
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Y-mAbs Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Y-mAbs Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Y-mAbs Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Y-mAbs Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Y-mAbs Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Y-mAbs Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Y-mAbs Therapeutics's EV-to-EBITDA falls into.
Y-mAbs Therapeutics's current Enterprise Value is $601.33 Mil.
Y-mAbs Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Y-mAbs Therapeutics's PE Ratio for today is calculated as:
Y-mAbs Therapeutics's share price for today is $15.23.
Y-mAbs Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.490.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Y-mAbs Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Y-mAbs Therapeutics (Y-mAbs Therapeutics) Business Description
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. The vast majority of the Company's product sales are generated in the United States with additional sales outside the United States in China and Israel through sublicenses and distribution agreements.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
YMAB has been successfully added to your 